Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma Clinical Trial

Official title:

Single Arm, Open, Multicenter Phase II Clinical Study of Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04319471
• Other study ID #: NPC003.1
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: June 1, 2020
• Est. completion date: June 1, 2023

Study information

• Verified date: March 2020
• Source: Fujian Cancer Hospital
• Contact: Shaojun Lin, DR
• Phone: 8613860603879
• Email: linshaojun[@]yeah.net
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a randomized, phase II, prospective, multicenter clinical trial to evaluate the efficacy and safety of sufficient chemoradiotherapy plus oral capecitabine/S-1 for 1 year in the treatment of oligometastatic Nasopharyngeal Carcinoma

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 70
• Est. completion date: June 1, 2023
• Est. primary completion date: June 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Patients with oligometastatic nasopharyngeal carcinoma (newly diagnosed or after treatment) ; patients with first diagnosis of nasopharyngeal carcinoma diagnosed by pathological biopsy; metastatic focus in principle need biopsy pathological diagnosis; but if the patient refuses to take the metastatic biopsy, the clinician decides with clinical evidence

2. Patients with a ECOG score of 0,1 or 2 and an expected survival period of more than 6 months; those who can cooperate in observing adverse reactions and outcomes;

3. At least one tumor lesion can be measured according to recist 1.1 criteria

4. Have good organ function

5. Informed consent signed and dated indicating that the patient has been informed of all relevant aspects of the study ;

6. Patients who are willing and able to comply with visiting arrangements, treatment plans, laboratory tests, and other research procedures ;

7. Be willing to comply with arrangements during the study to no longer participate in any other clinical studies related to drugs and medical devices.

Exclusion Criteria:

1. Patients with severe history of rapid-onset allergy to any of the drugs used in this study ;

2. Patients with local and/or regional recurrence;

3. Combine with other malignancies in 5 years (except non-melanin skin cancer or pre-invasion cervical cancer);

4. Any of the following conditions existed during the first six months of screening:

myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery transplantation, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, or symptomatic pulmonary embolism. patients known to have coronary artery disease, congestive heart failure that does not meet the above criteria or left ventricular ejection fraction < 50% and must use an optimized stable medical protocol determined by the therapist, if appropriate, to consult a cardiologist ;

5. Active infections, including tuberculosis, hepatitis b, hepatitis c, and human immunodeficiency virus. Patients with hbv surface antigen (hbsag) positive but HBV DNA <1000 copies/ml are eligible to participate in the study ;

6. Idiopathic pulmonary fibrosis, drug-induced pneumonia, organic pneumonia (bronchiolitis obliterans),Chest CT scans showing evidence of active pneumonia during history or screening of idiopathic pneumonia;

7. Substance abuse or alcohol addiction

8. Inability or limitation of civil capacity ;

9. Patients with physical or mental disorders who, according to the researchers, can not fully or fully understand the possible complications of the study ;

10. May increase the risk associated with the treatment of the study protocol, or may interfere with the interpretation of the study results and (as judged by the researchers) may render the patient unfit to participate in other severe acute or chronic medical conditions (including immune colitis, inflammatory bowel disease, non-infectious pneumonia, pulmonary fibrosis) or mental disorders (including dementia and epilepsy, recent, past year or active suicidal ideation or behavior) or laboratory abnormalities ;

11. Patients with expected survival <6 months ;

12. Previous diagnosis of immunodeficiency or known Human Immunodeficiency Virus (HIV) or acquired immunodeficiency syndrome (aids)-related diseases ;

13. Male or female pregnant or lactating women who have fertility but are unwilling or unable to use contraception throughout the study period and at least one year after the treatment programme ;

14. Large amounts of glucocorticoids or other immunosuppression have been used within 4 weeks of treatmen

Related Conditions & MeSH terms

• Carcinoma
• Nasopharyngeal Carcinoma

Intervention

Drug:
• Capecitabine/S-1
Drug: Capecitabine/S-1
• Chemotherapy
Gemcitabine (1000mg/m2) D1 D8+ nidaplatinum (80-100mg/m2) D2 q3w ×4-6cycle

Radiation:
• Head and neck radiotherapy
IMRT is uesd for the synchronous oligometastatic Nasopharyngeal Carcinoma;

Other:
• Local Consolidative Therapy
radiotherapy,surgery or interventional therapy for all metastatic sites.

Locations

Country	Name	City	State
China	Department of radiation oncology, Fujian cancer hospital	Fuzhou	Fujian

Sponsors (3)

Lead Sponsor	Collaborator
Fujian Cancer Hospital	Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-Free Survival(PFS)	PFS was defined as the time from randomization to first documented disease progression (PD) using Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) or death from any cause, whichever occurred first. For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started or the appearance of 1 or more new lesions. For non-target lesions, PD was defined as the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions.	12 months and 24 months
Secondary	overall survival(OS)	OS was defined as the time from randomization to death from any cause	12 months and 24 months